Clinical Trial Update: Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial assessing osimertinib with or without bevacizumab as initial therapy for EGFR-mutant non-small cell lung cancer; the study is currently recruiting…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• TAGRISSO (osimertinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma | Phase 3 | Status: RECRUITING